Abstract

Provided is a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as defined herein for use in the treatment or prevention of a Dirofilaria infection in a mammal, Provided is a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as defined herein for use in the treatment or prevention of a Dirofilaria infection in a mammal, Provided is a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as defined herein for use in the treatment or prevention of a Dirofilaria infection in a mammal, The compounds are also for use in the treatment or prevention of diseases or conditions caused by a Dirofilaria infection in a mammal. Also described are corresponding methods of treating or preventing a Dirofilaria infection in a mammal.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 33/10 - Anthelmintics

Abstract

The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof. The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof. The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae I and II, and to the use of compounds of Formulae I and II in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 239/86 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in position 4
• C07D 495/04 - Ortho-condensed systems

Abstract

The disclosure herein are materials and methods for the treatment of snake bite. Aspects of the disclosure includes pharmaceutical compositions, and kits, both of which may be of use in the treatment of snake bite.

IPC Classes  ?

• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61P 39/02 - Antidotes

Abstract

DirofilariaDirofilariaDirofilariaDirofilaria infection in a mammal.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 33/10 - Anthelmintics

Abstract

The present invention relates to chimeric proteins, to compositions comprising such proteins and to the medical uses of such proteins and compositions. In particular the proteins or compositions of the invention may be used in the prevention or treatment of autoimmune diseases or inflammatory diseases, or for the prevention or treatment of diseases mediated through binding of sialic acid dependent receptors, or as vaccines or as anti-cancer agents. One aspect of the invention relates to a chimeric Fc receptor binding protein which comprises two chimeric polypeptide chains, wherein each chimeric polypeptide chain comprises an immunoglobulin G heavy chain constant region, a tailpiece region and a hinge region, wherein the amino acid sequence of each polypeptide chain possess a sugar moiety at or close to the N-terminus and a sugar moiety at or close to the C-terminus, and their use in the treatment or prevention of a disease mediated by a pathogen that relies on sialic acid receptors interactions.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 239/86 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in position 4
• C07D 495/04 - Ortho-condensed systems

Abstract

The present invention relates to chimeric proteins, to compositions comprising such proteins and to the medical uses of such proteins and compositions. In particular the proteins or compositions of the invention may be used in the prevention or treatment of autoimmune diseases or inflammatory diseases, or for the prevention or treatment of diseases mediated through binding of sialic acid dependent receptors, or as vaccines or as anti-cancer agents. One aspect of the invention relates to a chimeric Fc receptor binding protein which comprises two chimeric polypeptide chains, wherein each chimeric polypeptide chain comprises an immunoglobulin G heavy chain constant region, a tailpiece region and a hinge region, wherein the amino acid sequence of each polypeptide chain possess a sugar moiety at or close to the N-terminus and a sugar moiety at or close to the C- terminus, and their use in the treatment or prevention of a disease mediated by a pathogen that relies on sialic acid receptors interactions.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The invention relates to fusion polypeptides derived from IgG. The fusion polypeptides comprise a domain derived from an immunoglobulin heavy chain constant region; and a plurality of hinge regions derived from IgG hinge sequences. The invention also relates to nucleic acids encoding the fusion polypeptides, and to proteins comprising two fusion polypeptides of the invention. Also provided are a pharmaceutical composition comprising a fusion polypeptide and/or protein of the invention, and medical uses of the polypeptides, proteins, or compositions.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and/or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 16/46 - Hybrid immunoglobulins
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/47 - QuinolinesIsoquinolines
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• A61P 31/04 - Antibacterial agents
• A61P 33/00 - Antiparasitic agents
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.

IPC Classes  ?

• A61K 31/365 - Lactones
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and/or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/04 - Antibacterial agents

Abstract

h increases the likelihood of delivering a lethal dosage of insecticide to mosquitoes flying in frequently-visited areas of a bed net, without increased attendant health risk to a user.

IPC Classes  ?

• A01M 1/20 - Poisoning, narcotising, or burning insects
• A01M 29/34 - Scaring or repelling devices, e.g. bird-scaring apparatus preventing or obstructing access or passage, e.g. by means of barriers, spikes, cords, obstacles or sprinkled water specially adapted for insects
• A47C 29/00 - Nets for protection against insects in connection with chairs or bedsBed canopies
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• A45F 3/52 - Nets affording protection against insects
• A01N 43/30 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with two or more hetero atoms five-membered rings with two hetero atoms in positions 1,3 with two oxygen atoms in positions 1,3, condensed with a carbocyclic ring

Abstract

The present invention pertains to the use of tylosin A and its analogs and derivatives in prevention or treatment of filariasis. In particular, the present invention pertains to the use of tylosin A or a salt thereof or a compound having a structure of Formula (I) in prevention or treatment of filariasis.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 33/10 - Anthelmintics
• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.

IPC Classes  ?

• A61K 31/365 - Lactones
• C07H 17/00 - Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

Provided are polymeric proteins that comprise two or more polypeptide monomer units, each monomer unit comprising two chimeric protein chains. Each chimeric polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions,wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit. Each chimeric protein chain also comprises a modified immunoglobulin M tailpiece region, wherein the amino acid sequence of each chimeric polypeptide monomer comprises an alteration of the primary structure as compared to the native sequences from which the immunoglobulin G heavy chain constant region or immunoglobulin M tailpiece region are derived, and the alteration changes the number of glycosylation sites in a manner that promotes polymerisation. This promotion of polymerisation may lead to the generation of tetrameric, hexameric, and even dodecameric forms of the proteins. The proteins are suitable formedical uses,such as in the prevention or treatment of autoimmune diseases such as idiopathic thrombocytopenia. Also provided are methods of treatment using the polymeric proteins, and pharmaceutical compositions comprising the polymeric proteins.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Mosquito bed net assembly 10a-h includes a mosquito bed net (12) impregnated with a first insecticide and a barrier member 16a-h located above an upper surface (14) of the bed net (12) and being impregnated with a second insecticide. In use, bed net assembly 16a-h increases the likelihood of delivering a lethal dosage of insecticide to mosquitoes flying in frequently-visited areas of a bed net, without increased attendant health risk to a user.

IPC Classes  ?

• A47C 29/00 - Nets for protection against insects in connection with chairs or bedsBed canopies
• A45F 3/52 - Nets affording protection against insects
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group

Abstract

Provided is a method for identifying human immunodeficiency virus (HIV) in a sample. The invention involves use of a plurality of fluorescently labeled oligonucleotide probes and flow cytometry to detect the presence or absence of HIV in macrophages that are obtained from a mucosal surface. The invention is particularly useful for detecting HIV infection prior to seroconversion.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject.

IPC Classes  ?

• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

Provided is a method for identifying human immunodeficiency virus (HIV) in a sample. The invention involves use of a plurality of fluorescently labeled oligonucleotide probes and flow cytometry to detect the presence or absence of HIV in macrophages that are obtained from a mucosal surface. The invention is particularly useful for detecting HIV infection prior to seroconversion.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions

Abstract

The present invention relates to antimalarial compounds. More specifically, the present invention relates to novel substituted quinolone derivatives of formula (I) and related quinoline derivatives of formula (II) as defined herein that possess potent antimalarial activity. The present invention also relates to processes for the preparation of these quinolone and quinoline derivatives, to pharmaceutical compositions comprising them and to their use as therapeutic agents for the treatment and/or prevention of malaria.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to dispiro tetraoxane compounds of formula (VII) which may find application in the treatment of malaria.

IPC Classes  ?

• C07D 323/04 - Six-membered rings
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/539 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g dioxazines
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to a method suitable for but not limited to measuring levels of insecticide compounds such as DDT [(1, 1, 1-trichloro-2, 2-bis (p-chlorophenyl) ethane]. More specifically the present invention relates to a method suitable for measuring the level of xenobiotics, for example DDT in field applications using recombinant glutathione-S transferase enzymes (GST) and either colorimetric detection agents or potentiometric sensors and to a kit for performing same.

IPC Classes  ?

• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

A compound having the formula (I) wherein ring A represents a substituted or unsubstituted monocyclic or multicyclic ring; m=any positive integer; n=0-5; X=CH and Y=-C(O)NR1R2, -NR1R2 or -S(O)2R4, where R1, R2 and R4 are each individually selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring, or any combination thereof, or R1 and R2 are linked so as to form part of a substituted or unsubstituted heterocyclic ring, or X=N and Y=-S(O)2R3 or -C(O)R3, where R3 is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring or any combination thereof.

IPC Classes  ?

• C07D 323/04 - Six-membered rings
• C07D 491/10 - Spiro-condensed systems
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Goods & Services

Printed matter; stationery; instructional and teaching material (except apparatus); publications; brochures. Charitable fund-raising services. Education; providing of training; conferral of degrees, diplomas and certificates and other qualifications; arranging and conducting seminars, symposiums, conferences, workshops; teaching, lecturing and tutorial services; educational examinations; library services; information, advisory and consultancy services all relating to the aforesaid. Scientific and technological services and research and design relating thereto; research and development of products; genetic, laboratory, medical, pharmaceutical, biological, molecular and immunology research and development services; provision of research services; research relating to tropical, parasitic and infectious diseases, development of drugs, vaccines and diagnostics, vector control, veterinary diseases, child and reproductive healthcare and health services; social science research services; conducting clinical trails; information, advisory and consultancy services in relation to the aforesaid. Medical services; travel health clinic services; medical analysis for the diagnosis and treatment of persons; X-ray examinations; taking of blood samples; pharmacy advice; administering of injections, vaccines and tablets; provision of information relating to vaccination for overseas travel; information, advisory and consultancy services relating to the aforesaid.

Abstract

The present invention concerns peptide mimeotopes of carbohydrates found on the cell surface of capsular bacteria and also smooth gram negative bacterium with lipopolysaccharide on the cell- surface. The peptides may be used as vaccines against bacterial infections such as meningitis, septicaemia or pneumonia. The invention also concerns nucleic acids encoding such peptide that may be used in DNA vaccines against such bacteria.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/09 - Recombinant DNA-technology